Published in Hepatitis Weekly, October 4th, 2004
AMD is the leading cause of visual impairment affecting more than 1.5 million adults over the age of 50 in the United States. The filing of the IND is an important milestone for Sirna Therapeutics, the leader in RNA interference (RNAi) drug development, and it marks a significant next step in the company's plan to transition its platform RNAi technology from the research lab to patients.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.